Supernus Pharmaceuticals (SUPN) Shares Outstanding (Diluted Average) (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 13 years of Shares Outstanding (Diluted Average) data on file, last reported at $56.5 million in Q4 2025.

• Shares Outstanding (Diluted Average) for Q4 2025 came in at $56.5 million, up 0.88% year-over-year; the trailing twelve-month figure through Dec 2025 was $56.5 million (up 0.88% YoY), and the FY2025 annual result was $56.5 million, up 0.88% from the prior year.
• Shares Outstanding (Diluted Average) improved to $56.5 million in Q4 2025 per SUPN's latest filing, from $56.1 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $62.5 million in Q1 2023 and troughed at $54.2 million in Q1 2021.
• A 5-year average of $57.0 million and a median of $55.9 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Diluted Average) climbed 13.47% in 2022, then dropped 11.23% in 2023.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $54.4 million in 2021, then rose by 13.47% to $61.7 million in 2022, then retreated by 10.01% to $55.5 million in 2023, then increased by 0.81% to $56.0 million in 2024, then increased by 0.88% to $56.5 million in 2025.
• Business Quant data shows SUPN's Shares Outstanding (Diluted Average) at $56.5 million in Q4 2025, $56.1 million in Q3 2025, and $56.7 million in Q2 2025.